The post-marketing safety of venlafaxine: a real-world two-decade pharmacovigilance study using the FAERS database
Top Cited Papers
Open Access
- 21 January 2026
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 17, 1737113
Abstract
Objective: Venlafaxine, a serotonin-norepinephrine reuptake inhibitor widely prescribed for major depressive disorder and related conditions, remains insufficiently characterized regarding its adverse event profile. This study aimed to comprehensively evaluate the post-marketing safety of venlafaxine using data from the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: The data were extracted from the FAERS database from the first quarter (Q1) 2004 to Q2 2025. Adverse drug events were analyzed using the Reporting Odds Ratio (ROR), Bayesian Confidence Propagation Neural Network (BCPNN), Proportional Reporting Ratio (PRR), and Multi-Item Gamma Poisson Shrinker (MGPS) methods. Results: A total of 47,325 venlafaxine-related adverse event reports were analyzed. Disproportionality analysis revealed significant signals for drug ineffectiveness (n = 2,108, ROR = 1.6, PRR = 1.6, χ 2 = 483.4, IC = 0.7, EBGM = 1.6), drug hypersensitivity (n = 1,014; ROR = 4.9, PRR = 4.8, χ 2 = 2998.7, IC = 2.2, EBGM = 4.7), and anxiety (n = 198, ROR = 4.3, PRR = 4.2, χ 2 = 2202.0, IC = 2.0, EBGM = 4.1). Strongest signals (EBGM = 9.9) were observed for suicide attempt, agitated depression, and renal dysplasia. Tachycardia (EBGM = 8.3) was the most frequently reported adverse event among patients under 18 years, while emotional disorder (EBGM = 9.5) predominated in those aged 65 years and older. Most adverse events (39.3%) occurred within the first 30 days of venlafaxine therapy initiation. Conclusion: This pharmacovigilance analysis systematically identified significant safety signals associated with venlafaxine. The findings provide important evidence to support safer clinical use of venlafaxine and may assist in optimizing individualized therapeutic decisions in practice.Keywords
This publication has 32 references indexed in Scilit:
- Which antidepressant doses are optimal?The Lancet Psychiatry, 2019
- Socio-economic variations in the mental health treatment gap for people with anxiety, mood, and substance use disorders: results from the WHO World Mental Health (WMH) surveysPsychological Medicine, 2017
- A systematic review and meta-regression of the prevalence and incidence of perinatal depressionJournal of Affective Disorders, 2017
- Motivational deficits in major depressive disorder: Cross-sectional and longitudinal relationships with functional impairment and subjective well-beingComprehensive Psychiatry, 2016
- Large-Scale Network Dysfunction in Major Depressive DisorderJAMA Psychiatry, 2015
- Suicidality in Pediatric Patients Treated With Antidepressant DrugsArchives of General Psychiatry, 2006
- Cost of Lost Productive Work Time Among US Workers With DepressionJAMA, 2003
- Efficacy of venlafaxine in patients with major depressive disorder who have unsustained or no response to selective serotonin reuptake inhibitors: an open-label, uncontrolled studyClinical Therapeutics, 2002
- SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depressionThe Lancet, 2000
- Mechanism of Sodium Channel Block by Venlafaxine in Guinea Pig Ventricular MyocytesThe Journal of Pharmacology and Experimental Therapeutics, 1999